Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18351064 | 0.91 | PAOX (0.38) | PAOXALDH1A1HTR1AMC4RSIGMAR1 | |
| SCHEMBL1655253 | 0.91 | PAOX (0.38) | PAOXALDH1A1HTR1AMC4RSIGMAR1 | |
| SCHEMBL13698377 | 0.91 | PAOX (0.38) | PAOXALDH1A1HTR1AMC4RSIGMAR1 | |
| SCHEMBL26744681 | 0.91 | SMN1; SMN2 (0.35) | ALDH1A1HSD11B1SMN1; SMN2CHRNA7 | |
| SCHEMBL2560152 | 0.91 | SMN1; SMN2 (0.35) | ALDH1A1HSD11B1SMN1; SMN2CHRNA7 | |
| SCHEMBL29300025 | 0.91 | SMN1; SMN2 (0.35) | ALDH1A1HSD11B1SMN1; SMN2CHRNA7 | |
| SCHEMBL21321887 | 0.91 | SMN1; SMN2 (0.35) | ALDH1A1HSD11B1SMN1; SMN2CHRNA7 | |
| SCHEMBL26744647 | 0.91 | SMN1; SMN2 (0.35) | ALDH1A1HSD11B1SMN1; SMN2CHRNA7 | |
| SCHEMBL26202000 | 0.86 | SIGMAR1 (0.37) | PAOXALDH1A1SIGMAR1PKM | |
| SCHEMBL16582330 | 0.82 | SIGMAR1 (0.38) | ALDH1A1SMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | PAOX 2831/4885ALDH1A1 2048/4885HSD11B1 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.